BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 227
- Registration Number
- NCT06233942
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Florida Cancer Specialist Research Institute Lake Nona, Orlando, Florida, United States
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorHormone Receptor Positive Malignant Neoplasm of BreastAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung CancerHormone Receptor Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT06120283
- Locations
- 🇺🇸
Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06091943
- Locations
- 🇨🇳
Jining No Peoples Hospital East Branch, Jining, Shandong, China
🇨🇳Deyangs People Hospital, Deyang, Sichuan, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- CLL
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT06073821
- Locations
- 🇺🇸
Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT06029127
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 118
- Registration Number
- NCT06010303
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 217
- Registration Number
- NCT05981703
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia RefractoryWaldenstrom's Macroglobulinemia RecurrentWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT05952037
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorSolid Tumor
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT05935098
- Locations
- 🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 160
- Registration Number
- NCT05909904
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Stanford Medicine, Stanford, California, United States
🇺🇸Rocky Mountain Cancer Centers, Llp(Us Oncology Research), Lone Tree, Colorado, United States